Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy

At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. This is the first definitive morbidity and mortality study to assess a potential therapy for cardiac disease in this underserved patient population.

VIDEO | Aflac Cancer Center: Ethan's Story

Kids like Ethan are why Aflac has been a corporate ally for the childhood cancer community for 24 years. Through innovative research and helping provide peace of mind to patients and their families, Aflac’s commitment to helping find a cure for pediatric cancer holds strong. Every child deserves a lifetime.

Novo Nordisk Publishes Integrated 2018 Annual Report

Novo Nordisk has published its integrated 2018 Annual Report detailing the company’s year-end performance. The report highlights the company’s progression towards long-term targets taking an integrated approach that accounts for financial, social and environmental performance.

J&J Exec: Tuberculosis is a Global Emergency. It's Time to Start Treating it That Way

Four years ago, a disease that rarely made headlines — Ebola — raged in West Africa. There was no vaccine, treatment or cure. Though the initial response was slow, the international community ultimately mobilized resources, developed scientific innovations and promised to make sure a tragedy on the same scale would never happen again.

Meet a Johnson & Johnson Researcher Poised to Crack the HIV Vaccine Code

In 1992, as a young HIV/AIDS researcher in her native Netherlands, Hanneke Schuitemaker, Ph.D., now Vice President, Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V., was devoted to learning as much as she could about the disease—and saw her role as that of a researcher, rather than someone who closely interacted with people who were living with HIV.

Merck Fellows Share Skills for Drug Discovery

As part of the prestigious Merck Fellowship for Global Health program, IDRI (Infectious Disease Research Institute) is hosting three Fellows in Seattle for three months to assist IDRI scientists in implementing drug metabolism and pharmacokinetic (DMPK) studies, a critical compon

Merck Fellowship for Global Health and PNRI Partner to Advance Promising Antifungal

The Pacific Northwest Research Institute (PNRI) is partnering with three Fellows from the Merck Fellowship for Global Health program to create a comprehensive plan to move a promising antifungal agent from the laboratory to clinical practice. The compound, discovered in the labor

Astellas Brings Light to the Lives of Cancer Patients

To help brighten the darkest moments of patients’ cancer treatment journeys, LLS created the Light The Night campaign. A series of fundraising walks across the country, Light The Night benefits research to find blood cancer cures and improve the quality of life for patients and their families.

Novartis Rises to Second Place in 2018 Access to Medicine Index

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.

Corporate Giving Increased for a Third Consecutive Year, up 15% Since 2015

In the largest, most robust, industry-leading, and internationally-recognized research of corporate social investment, CECP: The CEO Force for Good, in association with The Conference Board, found in their annual Giving in Numbers: 2018 Edition report that leading corporations are intensifying efforts to meet key societal needs around the world.

Latest Campaigns

  1. Innovation & Sustainable Solutions
    Chemours chemistry is essential to our daily lives, global commerce, and the future. Our commitment to product sustainability drives us to innovate...
  2. Drawdown Georgia
    Informed by Project Drawdown, the world’s leading resource for climate solutions, Drawdown Georgia is the first state-centered effort to crowdsolve...
  3. Leadership
    Cascale demonstrates industry leadership and collaboration to drive collective action, by sharing insight into key sustainability topics inside and...
  4. License to Operate
    Corporate governance, risk management, operational integrity, and regulatory compliance are demanding challenges that companies face in today’s ever...
  5. International Paper | HEALTHY & ABUNDANT FORESTS
    Vision 2030 Goal: Lead forest stewardship efforts globally
  6. Sustainable Products and Innovation
    Ongoing research into innovative solutions enables CNH’s brands to manufacture products that respect the environment while satisfying customers’...
  7. Goals That Inspire: Positive Social Impact
    Through our Goals That Inspire we strive to make a positive difference in our communities by relying on our ability to understand their needs and then...
  8. Communities We Serve
    Albertsons Companies stores are much more than a place to buy groceries. We're part of your neighborhood, and we believe in making each of our...
  9. Environmental Sustainability
    As sustainability leaders, we implement our sustainability strategy across all company activities along the entire value chain, from raw materials to...